Mablink Bioscience is a French-based biotechnology company specialized in the development of an emerging class of cancer drugs, called antibody-drug conjugates (ADCs). Mablink leverages its patented hydrophilic technology PSARlink™ that enables the design of homogenous, plasma-stable next generation ADCs with a high DAR, whilst retaining excellent pharmacological properties, in order to quickly bring new and better treatment options to cancer patients.